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Behc ¸et’s disease (BD) is a chronic, relapsing, and debilitating systemic vasculitis of unknown aetiology with the clinical features
of mucocutaneous lesions, ocular, vascular, articular, neurologic, gastrointestinal, urogenital, and pulmonary involvement. The
disease is much more frequent along the ancient “Silk Route” extending from Eastern Asia to the Mediterranean basin, compared
with Western countries. The disease usually starts around the third or fourth decade of life. Male sex and a younger age of
onset are associated with more severe disease. Although the treatment has become much more eﬀective in recent years, BD is
still associated with severe morbidity and considerable mortality. The main aim of the treatment should be the prevention of
irreversible organ damage. Therefore, close monitoring, early, and appropriate treatment is mandatory to reduce morbidity and
mortality. The treatment is mainly based on the suppression of inﬂammatory attacks of the disease using immunomodulatory
and immunosuppressive agents. In this paper, current state of knowledge regarding the therapeutic approaches is outlined. To
provide a rational framework for selecting the appropriate therapy along the various treatment choices, a stepwise, symptom-
based, evidence-based algorithmic approach was developed.
1.Introduction
Behc ¸et’s disease (BD) is a chronic, relapsing, and debilitating
systemic vasculitis of unknown aetiology with the clinical
features of mucocutaneous lesions, ocular, vascular, articu-
lar, neurologic, gastrointestinal, urogenital, and pulmonary
involvement [1]. BD usually starts around the third or
fourth decade of life. Recent epidemiologic surveys [2–4]
suggest that sex distribution is roughly equal. The disease
is particularly prevalent in “Silk Route” populations but has
global distribution. The pravelance of the disease is 14–
20 per 100000 along the Silk route [5]. Turkey has the
highest prevalence. Azizlerli et al. from Istanbul reported
the prevalence of the disease to be nearly 1/250 of the
population aged 12 or older [2]. BD is rarely seen in western
countries. The pravelance of the disease in England is less
than 1/100000 [5, 6]. This marked geographic variation of
BDcanbeexplainedbythegeneticbasisofthediseaseand/or
environmental triggers. The diagnosis is based on clinical
criteria, as there is no pathognomonic test. Although several
immunological abnormalities have been demonstrated, the
exact mechanism of the inﬂammatory changes occurring
remains to be elucidated. The most probable hypothesis is
that of an inﬂammatory reaction set oﬀ by infectious agents
such as herpes simplex virus 1 or Streptococcus spp. or by
an autoantigen such as heat shock proteins in genetically
predisposed individuals [7–9].
Mucocutaneouslesionsﬁgureprominentlyinthepresen-
tation and diagnosis and may be considered the hallmarks of
BD. Oral ulcers (OUs), genital ulcers (GUs), and cutaneous
lesions together with ocular lesions and arthropathy are
the most frequent features of the disease in all countries.
Mucocutaneous lesions often precede other manifestations.
Therefore,theirrecognitionmaypermitearlierdiagnosisand
treatment, with salutary results [5]. OUs are characterized by
recurrent and painful ulcerations of the oral mucosa. They
are identical to aphthae in appearance, but they tend to be
more frequent and multiple. The most common sites are
the mucous membranes of the lips, buccal mucosa, tongue,
and soft palate. GUs are similar in appearance and course to
OUs, but may not recur as often. They are usually deeper
than the OUs and have a scarring tendency. The labia is
the most frequently involved site in females and scrotum
in males. Relapsing bipolar oral and genital ulcers are
strongly evocative of BD [5]. Papulopustular lesions (PPLs)2 Pathology Research International
are sterile, folliculitis, or acne-like lesions on erythematous
base which appear as a papule and in the course of a
24–48 hours become pustule. Trunk and the lower limbs
are the most common locations [10]. Erythema nodosum
(EN) is mostly seen in females and occur in about one-
third of all patients. They have a typical clinical presentation
with bilateral, pretibial, painful, and hot erythematous
nodules. Other cutaneous lesions such as Sweet’s syndrome-
like,pyodermagangrenosum-like,erythemamultiforme-like
lesions, extragenital ulcers, and palpable purpura can be seen
during the course of the disease [1, 5, 11]. The skin pathergy
test is a nonspeciﬁc skin hyperreactivity, induced by needle
prick. The test positivity is deﬁned as the development of a
papule or pustule at the needle-prick site at 48h. It is more
strongly positive among males. Test positivity varies between
geographic areas and has been reported to be high especially
in Japan and the Mediterranean Sea countries (50–70%) [5].
Ocular involvement is a serious complication of BD
and is characterized by repeated, explosive inﬂammatory
attacks that may lead to visual loss in almost 15% of eyes.
Panuveitis is the most frequent ocular lesion in BD. Anterior
uveitis, posterior uveitis, and retinal vasculitis are the other
main ocular manifestations. They are bilateral in most of
the patients [12]. Articular involvement is characterized
by nonerosive and nondeforming arthritis which often
presents with monoarticular pattern, although asymmetrical
polyarthritis can occur. The articular involvement is usually
transient in nature with episodes lasting from a few days
to weeks [13]. The disease is a systemic vasculitis aﬀecting
arteries and veins of various sizes. Venous system is the
major aﬀected site, and subcutaneous thrombophlebitis is,
indeed, the most frequent type of venous involvement.
Thromboses of the inferior vena cava and superior vena
cava, dural sinuses, and Budd-Chiari syndrome can also be
seen and are associated with poor prognosis. Pulmonary
arterial aneurysm is rare; however, it is important cause of
mortality [14]. Neurological involvement is relatively rare,
but one of the most serious complications of the disease due
to its grave prognosis. Parenchymal involvement including
brainstem involvement, hemispheric manifestations, spinal
cord lesions, and meningoencephalitis is seen in the majority
of patients (%80). Dural sinus thrombi presenting with
headaches and papilledema appear in 20% of patients
with neurological involvement and have a more bening
course [15]. Gastrointestinal involvement is characterized
by aphthous-like mucosal ulcers occuring predominantly in
the iliocaecal region, although it can occur throughout the
gastrointestinal tract [16].
BD runs a chronic course with unpredictable exacerba-
tions and remissions. In a recent multicenter study [17],
we aimed retrospectively to determine the occurrence of
the symptoms in chronologic order. We also evaluated the
inﬂuence of the treatment and followup on the clinical
severity and tried to obtain the factors determining the
severe organ involvement in 661 patients. OUs were the most
common manifestation (100%) followed by GUs (85.3%),
PPLs (55.4%), EN (44.2%), skin pathergy reaction (37.8%),
and articular (33.4%) and ocular involvement (29.2%).
OUs were the most common onset manifestation (88.7%)
which was followed by GUs (14.2%), EN (5.7%), and ocular
involvement (4.2%). The duration between the onset symp-
tom and the fulﬁlment of diagnostic criteria was calculated
to be 4.3 ± 5.7 years. The frequency of ocular involvement
and GUs was signiﬁcantly higher in patients whose disease
onset was less than 40 years. GUs, ocular involvement, PPLs,
thrombophlebitis, and skin pathergy reaction were found
to be signiﬁcantly higher in males. The clinical severity of
the disease showed a signiﬁcant increase in noncompliant
treatment group compared with compliant group with the
passage of time. Our study showed that mucocutaneous
lesions are the hallmarks of the disease, and especially OUs
precede other manifestations. Male sex and a younger age of
onset are associated with more severe disease.
Each or any combination of mucocutaneous, articular,
and ocular symptoms of the disease may have signiﬁcant
pain or loss in function, or both. Besides considerable
morbidity, the disease confers an increased mortality, mainly
due to large vessel (especially pulmonary arterial) and
neurologic involvement as well as bowel perforation. In
general, mortality ratios as well as mucocutaneous and
articular manifestations tend to decrease signiﬁcantly with
the passage of time. Both the onset of eye disease and its
greatest damage are usually within the ﬁrst few years of
disease onset. A recent study [14] has shown that neurologic
and large vessel involvements are exceptions, and they
can have their onset late (5–10 years) during the disease
course. In our multicenter study [17], in addition to these
involvements, gastrointestinal involvement was also found
to be a late manifestation of the disease. Therefore, all
these results stress the importance of vigilance in long-
term surveillance of patients with BD. Close monitoring
and appropriate treatments are mandatory to decrease the
morbidity and mortality of the disease since the disease
shows a continuous activity.
2. Treatment
Treatment of the disease has become much more eﬀective
in recent years because of advances in understanding the
pathogenesistheunderlyingdiseaseandavailabilityofawide
spectrum of therapeutic agents. Although several eﬀective
treatments currently exist, none of them result in a cure
of the disease and some are associated with signiﬁcant side
eﬀects. The choice of treatment is generally based on the
clinical presentation and the site aﬀected. However, the main
aim of the treatment should be the prevention of irreversible
organ damage, especially, during the early, active phase of
the disease. Close monitoring and appropriate treatment
may control and change the course of the disease. It is wise
to remember that especially male patients and those with
early onset disease are associated with more severe presenta-
tions including major vessel disease, ocular, gastrointestinal,
and neurological involvement and, therefore, require more
aggressive treatment [18].
This paper overviews the current state of knowledge
regarding the therapeutic approaches for BD. Based on
the mainly controlled studies and personal experience in
clinical practice and basic research in this ﬁeld, a stepwise,Pathology Research International 3
symptom-based, evidence-based algorithmic approach for
the management of BD was proposed. This approach might
enable clinicians to rationalize and further increase the
selection of the most appropriate therapy among numerous
treatment options [18].
2.1. Topical Treatment. The majority of experience in the
treatment of OUs comes from the studies performed in
patients with recurrent aphthous stomatitis (RAS). As we
mentioned before, OUs of BD are identical to RAS in
appearance. Therefore, therapeutic remedies related with
RAS, to some extent, can be applied to OUs of BD.
Although controlled studies are still lacking, the eﬃcacy
of topical corticosteroids is indisputable based on their favor-
able and widespread use. Topical corticosteroids suppress
the inﬂammation associated with the formation of aphthae,
and they are eﬀective on both OUs and GUs especially
when they are used in the early stage of these lesions. They
reducethepainseverityandhealingduration.Triamcinolone
acetonide as cream 0.1% in Orabase or spray, prednisolone
tablets in 20mL water as rinse four times daily like those of
dexamethasone elixir (0,5mg/5mL) can be used for OUs.
Potent corticosteroid creams alone or in conjunction with
antiseptics are also eﬀective in GUs. Major OUs or GUs
can be treated by intralesional triamcinolone, 5–10mg/mL.
Topically applied corticosteroid eye drops may also be used
in mild attacks of anterior and intermediate uveitis together
with mydriatics or cycloplegic agents [19]. Antimicrobial
agents including antiseptic agents and antibiotics are used to
control microbial load [1]. Two controlled studies with anti-
septic agents, listerine mouth rinse [20], and chlorhexidine
gel [21] in RAS noted the eﬀectiveness on the pain severity
and duration. Triclosan, a broad-spectrum antibacterial
agent has been shown to reduce the number of aphthous
ulcers in a double-blind cross-over study in RAS patients
[22]. Antibiotics, especially tetracycline has been widely used
in OUs of BD for years. Tetracycline mouthwash (250mg
capsules dissolved in 5mL of water or ﬂavored syrup and
held in the mouth for about 2 minutes before swallowing
four times daily) decrease pain severity and duration of
OUs. A double-blind trial of tetracycline suspension showed
signiﬁcant reductions in ulcer duration, size, and pain in
RAS patients [23] .Ar e c e n ts t u d y[ 24] assessed 0.2 percent
minocycline and 0.25 percent tetracycline aqueous solution
mouthwash in patients with RAS in a clinical randomized
crossover trial. Minocycline mouthwashes as compared to
topical tetracycline rinses resulted in signiﬁcantly improved
pain control, by reducing the severity and duration of
pain. Cephalexin [25] and penicillin G [26] have also been
reported to be eﬀective antibiotics. Sucralfate (1g/5mL), 4
times daily, for 3-month duration as mouthwash, decreases
signiﬁcantly the frequency, healing time, and pain of OUs
and healing time and pain of GUs. The eﬀectiveness of the
sucralfate on the OUs frequency and healing time continue
during the posttreatment period in decreasing order [27].
This compound binds to ulcerated tissue and forms a
barrierandaugmentsulcerhealing.Recentcontrolledstudies
suggest that pimecrolimus, a topical immunomodulator,
twice a day seems to be safe and eﬃcient in the treatment
of genital ulcers, by accelerating the healing process and
shortening the pain duration [28, 29]. Amlexanox accelerate
the healing and decreases the pain severity of oral ulcers.
It has anti-inﬂammatory and antiallergic activities [30, 31].
Amlexanox is used in oral paste (5%) 4 times daily (after
meals and at bedtime) for 4–10 days. Anti-inﬂammatory
agents (benzydamine, diclofenac), anaesthetics (lidocaine 2–
5%, mepivacaine 1.5%, tetracaine 0.5–1% gels, or mucosal
ointments), and silver nitrate, in general reduce the pain
severity of aphthous lesions [5, 32, 33]. Recently, beneﬁcial
eﬀects of colony stimulating factor on the healing duration
and pain severity of OUs and GUs have been reported by our
group [34].
Inadditiontotheabove-mentionedtreatmentapproach-
es to OUs, patients should be advised to maintain good
dailyoralhygiene[35].Thesepatientsshouldavoidirritating
agents such as acid, crusty, hard, spicy, or salty nutrients
and alcoholic beverages. EN is treated topically like classic
EN. Wet dressings such as aluminium acetate 3–5% (Burow’s
solution) can be applied in early stage of these lesions. This
approach is also helpful for the treatment of superﬁcial
thrombophlebitis. All therapy should be combined with rest
in bed.
2.2. Systemic Treatment
2.2.1. Corticosteroids. Corticosteroids have been widely used
almost for all lesions of the disease. The compound is
an eﬀective choice especially in mucocutaneous lesions,
acute uveitis, and neurologic disease. They can be given as
monotherapy or in combination with other drugs such as
colchicine,interferon(IFN)-α,cyclosporine,orazathioprine.
However, in a recent randomized, placebo-controlled study
of86patientswhohadactivemucocutaneouslesionswithout
eye and major organ involvement, low dose depot steroid
(40mg of methylprednisolone acetate every 3 weeks) was
only found to be helpful in controlling EN, especially
among females [36]. However, this result does not mean the
compound is not eﬀective in daily and/or higher doses. On
the other hand, the well-known side eﬀect proﬁle limits their
long-term use, and more corticosteroids do not improve the
long-term outcome.
2.2.2. Colchicine. Colchicine inhibits the enhanced chemo-
tactic activity of neutrophils. Promising results with
colchicine (0.5–2mg/d p.o.) have been reported especially
in mucocutaneous and articular ﬁndings. The ﬁrst placebo-
controlled study suggested that the drug is eﬀective only for
EN and arthralgia [37]. Yurdakul et al., in a randomized
placebo-controlled study [38], revisited the issue and have
shown that colchicine reduces the occurrence of GUs, EN,
and arthritis among women and the occurence of arthritis
among men. Although oligozoospermia, amenorrhea, or
dysmenorrhea,malaise,hairloss,gastrointestinalcomplaints
(nausea, vomiting, diarrhea), and hematologic side eﬀects
a r er e c o r d e da st h em a i na d v e r s ee ﬀects of colchicine, Yur-
dakul et al. [38] reported no signiﬁcant diﬀerence between
the groups.4 Pathology Research International
Recently, Davatchi et al. [39], in a large cohort of BD
patients (169 patients without major organ involvement),
reevaluated the eﬃcacy of colchicine. In this randomized,
double-blind, controlled crossover trial, the overall disease
activity index and OUs, GUs, PPLs, and EN improved
signiﬁcantly with colchicine. There was not any signiﬁcant
diﬀerence between the results for males and females.
2.2.3. Benzathine Penicillin. Calguneri et al. [40]h a v ef o u n d
thatthecombineduseofcolchicineandbenzathinepenicillin
(1.2MU/3 weeks) treatment more eﬀective than colchicine
alone. Combined treatment was eﬀective in reducing fre-
quency and duration of OUs and EN and the frequency
of GUs. Combined treatment also signiﬁcantly reduced the
number of arthritis episodes and prolonged the duration of
episode-freetimecomparedwiththecolchicine-alonegroup.
Recently Al-Waiz et al. [41] showed that combined use of
colchicine (1g/d) and benzathine penicillin (1.2MU/m) is
more eﬀective in decreasing clinical manifestation index, the
numerical sum of the clinical features, than in either drug
alone.
2.2.4. Rebamipide. In a double-blind, placebo-controlled
study of 35 BD patients, having as the main symptom OUs,
Matsuda et al. [42] used rebamipide (300mg/day) for 3 to 6
months. They reported that the rate of moderate or marked
improvement in OUs count and pain was 36% in the placebo
group and 65% in the drug group. Authors concluded that
rebamipide may be useful in the treatment and prevention
of recurrences of OUs. No signiﬁcant adverse eﬀect has been
reported.
2.2.5.ZincSulfate. Inarecentcontrolledstudyof32patients,
Sharquie et al. [43] evaluated the eﬃcacy of zinc sulfate in a
double-blind, crossover study and reported an improvement
in the clinical manifestations index of mucocutaneous
lesions without any side eﬀect.
2.2.6. Dapsone. Dapsone also inhibits the enhanced chemo-
tacticactivityofneutrophilsandcanbeusedasanalternative
compound to colchicine. In a double-blind, crossover study
of 20 patients, Sharquie et al. reported signiﬁcant reductions
in the number, duration, and frequency of OUs and number
of GUs in dapsone-treated patients. This compound also
showed a signiﬁcant decrease in the frequency of EN and
PPLs. Arthritis and epididymitis were also signiﬁcantly
supressed by dapsone, but the eﬀect of the compound on
arthralgia failed to reach the level of statistical signiﬁcance
[44]. Hemolytic anemia and methemoglobinemia, which
can be severe in patients with glucose-6-phosphate dehy-
drogenase deﬁciency, are the main side eﬀects, which may
signiﬁcantly limit their use.
Despite the encouraging results of the last three studies,
a limited number of patients included, and a relatively short
follow-up periods were the main limitations.
2.2.7. Thalidomide. The drug selectively inhibits TNF-α
synthesis. In a randomised, double blind, placebo-controlled
study with 63 patients, a remission of OUs, GUs, and PPLs
was detected in 22% of the patients over 8 weeks. During
the 6-month treatment 30% of the patients remained free of
lesions. Thalidomide therapy, however, was associated with
exacerbation of EN [45]. In addition, the eﬀects of the drug
are temporary, and discontinuation of the treatment results
in recurrence of the OUs and GUs. The eﬀectiveness of the
thalidomide is lost about 20 days after discontinuation of
the drug. Neurological side eﬀects and teratogenic risc of
thalidomide limit the clinical application.
2.2.8. Azathioprine. Azathioprine, an important disease-
modifying compound, shows an anti-inﬂammatory eﬀect by
suppressing both cellular and humoral immune responses.
In a randomised, double-blind, placebo-controlled study
[46] of 73 patients, azathioprine has been found to be an
eﬀectivechoiceinOUsandGUsbesidesocularinﬂammation
and arthritis. Azathioprine was signiﬁcantly better than
placebo in preventing the development of new eye disease.
Therefore, the authors concluded that the drug can be used
prophylactically to prevent the eye involvement in young,
male patients presenting with severe mucocutaneous lesions.
Myelotoxicity, gastrointestinal complaints, immunosuppres-
sion, opportunistic infections, and hepatotoxicity are the
main side eﬀects.
2.2.9. Cyclophosphamide. Cyclophosphamide is the fast-
acting alkylating agent. It has been found as a beneﬁcial
therapeutic agent for eye disease and systemic vasculitis
(neurologic involvement and arterial aneurysms). In a
double-blind crossover study [47], it has been shown that
the combination of cyclophosphamide and corticosteroid
therapy is superior to corticosteroid therapy alone in eye
involvement. Myelosuppression, pulmonary ﬁbrosis, renal
toxicity, hemorrhagic cystitis, infertility, malignancy, and
alopecia are the major adverse eﬀects of cyclophosphamide.
Due to the severe toxicity, cyclophosphamide should be
selected in cases with clinically signiﬁcant disease who are
refractory to other agents.
2.2.10. Cyclosporin A. Cyclosporin A (CyA) is an immuno-
suppressant agent which selectively inhibits T lymphocytes.
The drug is capable of markedly ameliorating uveitis as
well as mucocutaneous lesions. CyA is still one of the most
eﬀective agents for the treatment of uveitis which reduces
the frequency of ocular exacerbations and improves visual
acuity. In a conrolled study of 96 patients with recurrent
uveitis, CyA (10mg/kg/d) has been shown to be superior to
colchicine (1mg/d) in decreasing frequency and severity of
ocular attacks [48]. In the study of BenEzra et al. [49], CsA
was more eﬀective than conventional therapy (prednisolone,
chlorambucil) in decreasing the active ocular inﬂammatory
processes and arresting the deterioration of visual acuity.
However, conventional therapy was superior to CsA in con-
trolling OUs, GUs, and arthritis. Elidan et al. [50]r e p o r t e d
that CyA is signiﬁcantly better than conventional therapy
(prednisolone, chlorambucil) at improving hearing loss. Five
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improvement in their hearing loss. In a comparative study
[51], a signiﬁcant improvement in visual acuity during the
ﬁrst 6 months in CyA (5mg/kg/d) group compared with
cyclophosphamide (1000mg/mo) was observed. However,
this favorable eﬀect of CyA was not sustained in the followup
of patients up to 24 months. In another controlled trial
[52], 26 patients treated with CyA with a dose of 5mg/kg/d
have been compared with 50 patients receiving conventional
therapy, systemic corticosteroid alone or combined with
azathioprine. CyA treatment was found to be more eﬀective
in reducing OUs, GUs, cutaneous lesions, thrombophlebitis
as well as articular symptoms and neurologic symptoms.
T h e r e f o r e ,C y Ai sa l s oa ne ﬀective alternative for muco-
cutaneous lesions; however, it should be reserved for the
most severe cases because of its signiﬁcant long-term adverse
eﬀectssuchasrenalfailure,hypertension,neurologictoxicity,
and hirsutism. It is wise to remember that neurological
manifestations occur more frequently in BD patients under
CyA treatment [53].
2.2.11. Interferon-α. In recent years, the increasing evidence
suggests that interferon (IFN)-α is an eﬀective alternative in
the treatment of BD. The mode of action of IFN-α in BD
is still unknown. However, their antiviral and immunomod-
ulatory eﬀects appear to be the possible mechanisms. In
a randomised, double-blind, placebo-controlled study [54],
we have shown that IFN-α 2a treatment is an eﬀective alter-
native particularly for the management of mucocutaneous
lesions, and its eﬀect decreases gradually after the cessation
of treatment. IFN-α 2a treatment decreased signiﬁcantly the
duration and pain of OUs and the frequency of GUs and
PPLs. Although not signiﬁcant, the mean frequency and
duration of EN, thrombophlebitis, and articular symptoms
also showed a decrease. Hamuryudan et al. [55], in their 48-
week open, self-controlled trial, reported that IFN-alpha 2b
signiﬁcantly reduced the mean number of arthritis attacks.
IFN-α has also been employed in cases of sight-
threatening refractory uveitis with promising results. K¨ otter
et al. in their open-label, prospective study [56] used
IFN-α 2a in 50 patients at a dose of 6 million IU (MIU)
daily, tapered according to a preset schedule. The authors
concluded that IFN-α 2a is eﬀective in ocular BD, leading
to signiﬁcant improvement of vision and complete remis-
sion of ocular vasculitis in the majority of the patients.
Tugal-Tutkun et al. [57] evaluated the IFN-α treatment
in 44 patients with uveitis unresponsive to conventional
immunosuppressive therapy. Although the overall response
rate was 91%, complete response rate (36.4%) was lower
than that of the study of K¨ otter et al. In a newer study,
Onal et al. [58] investigated the long-term eﬃcacy and
safety of low dose (3.0MIU daily for 14 days, maintenance
dose, 3 MIU 3 times per week for 24 months) therapy of
IFN-α 2a in 37 patients with refractory Behc ¸et panuveitis
unresponsive to conventional immunosuppressive therapy.
During maintenance therapy, IFN-α 2a controlled uveitis
in 35 patients (95%). In 15 patients (41%), a maintenance
dosage of 3 MIU 3 times per week controlled uveitis without
any relapse. Remission rate after discontinuation of IFN-α
2a therapy was 76% by 3 months. Therapeutic response rate
diﬀerences of ocular BD with IFN-α treatment among the
respected studies might have been caused by the diﬀerent
patient populations studied and the diﬀerent dose schedules.
Nevertheless, taken together, IFN-α 2a seems to be able to
controlandachieveremissionofuveitisinmostpatientswith
refractory ocular BD.
The primary side eﬀects of IFN-α therapy are ﬂulike
symptoms (fever, chills, headache, fatigue, myalgia, etc.)
that start a few hours after the initiation of the therapy
a n dc o n t i n u el e s st h a nad a y .W eu s eo r a la c e t a m i n o p h e n
(paracetamol) 1000mg orally before injections and 500mg
after 6 hours during the ﬁrst weeks of the therapy to decrease
these side eﬀects. Nausea, vomiting, anorexia, diarrhea, loss
of weight, hematologic changes, transient raising of hepatic
transaminases are seen less frequently. Psychiatric side eﬀects
and depression are limiting factors for use of IFN-α.
2.2.12. Anti-TNF-α Agents. Several pieces of evidence indi-
cate that TNF-α plays a critical role in the pathogenesis of
BD, and so far, three anti-TNF-α compounds, inﬂiximab,
adalimumab, and etanercept, have shown favourable results
on preliminary tests. Almost all trials reported encouraging
results for recalcitrant mucocutaneous lesions besides ocular
and gastrointestinal symptoms, arthritis, and cerebral vas-
culitis. Anti-TNF-α treatment suppresses almost all mani-
festations of the disease with an immediate and dramatic
response. It also reduces the dosage of immunosuppressors.
Therefore, when the disease is associated with vital organ
involvement, especially in young male patients, anti-TNF-α
agents can also be used because of their potential to improve
the survival and prognosis.
The majority of current data related with inﬂiximab
comes from the uncontrolled, open studies, small case
series, and case reports. The main 3 prospective studies
performed by Sﬁkakis et al. [59], Ohno et al. [60], and
Tugal-Tutkun et al. [61] concentrated on the eye disease
and reported promising results. Besides these studies, many
small case series and case reports suggest that patients with
mucocutaneous lesions, gastrointestinal symptoms, arthritis
and cerebral vasculitis exhibit rapid and good responses to
inﬂiximab [62]. Recently, adalimumab, a fully humanised
anti-TNF-α antibody, has also been reported to be an
eﬀective alternative [63].
Melikoglu et al. [64] conducted the ﬁrst controlled
study of anti-TNF-α compound, etanercept. In a double-
blind, placebo-controlled study of 40 male patients, authors
reported that etanercept (25mg twice a week for 4 week) is
eﬀective in suppressing most of the mucocutaneous lesions.
The drug had a clear eﬀect on OUs and nodular lesions,
and the response was as early as the ﬁrst week. There was
a signiﬁcant decrease in the mean numbers of OUs and
nodular lesions as well as PPLs.
A recent position paper concluded that inﬂiximab is
recommendedasanadd-ontherapyforsevereBD,refractory
or intolerant to traditional immunosuppressive regimens.
Moreover, a single infusion of inﬂiximab (5mg/kg) can
be used as a ﬁrst-line agent for sight-threatening, bilateral
posterior eye segment inﬂammation, because the fast onset
of response is critical to prevent ﬁxed retinal lesions, and6 Pathology Research International
therefore,permanentvisualloss.Incasewhenocularrelapses
are not controlled by azathioprine and/or cyclosporin,
maintenance therapy with 5mg/kg doses of inﬂiximab every
6–8 weeks could be used for 2 years, provided no relapses
occur between intervals [62].
However, the high cost, the need for injections, trouble-
some toxic side eﬀects, and the inability to cure the disease
are the main limitations for widespread acceptance of anti-
TNF-α as a ﬁrst-line choice for the management of BD.
Optimal dosage and the long-term consequences are still
important questions for anti-TNF-α agents to be answered.
It still needs further controlled studies in large series.
Adverse eﬀects of anti-TNF-α agents include infection
(sinusitis, pharyngitis, bronchitis, and urinary tract infec-
tions, reactivation of tuberculosis), autoimmune reactions
(e.g., lupuslike syndrome), lymphoproliferative disorders,
delayed hypersensitivity reactions, and neurologic, cardiac,
and gastrointestinal symptoms.
2.2.13.Rituximab. Rituximabisachimericmonoclonalanti-
body against CD20, a B-cell diﬀerentiation marker. Recently,
Davatchi et al. [65] used rituximab in their randomized
single-blind controlled study. Twenty patients were ran-
domized to a rituximab group (in two 1000mg courses,
15-day interval) or cytotoxic combination therapy group.
Patients with rituximab group were also given methotrexate
(15mg/weekly) with prednisolone (0.5mg/kg per day).
The cytotoxic combination therapy group received pulse
cyclophosphamide (1000mg/monthly), azathioprine (2–
3mg/kg per day), and prednisolone (0.5mg/kg per day).
The authors concluded that rituximab was eﬃcient in severe
ocular manifestations of BD, and total adjusted disease
activity index improved signiﬁcantly after 6 months with
rituximab, but not with cytotoxic combination therapy
group.
2.2.14. Other Systemic Treatment Approaches. Several open
studies of methotrexate (7.5–20mg/1x week p.o. over 4
weeks) have reported the induction of an improvement of
a severe mucocutaneous involvement [66]a sw e l la sn e u r o -
logical [67, 68] and ocular involvement [69]. Methotrexate
is not recommended in pregnancy and lactation, and severe
bone marrow depression, liver dysfunction, acute infections,
renal insuﬃciency, and mucositis are important side eﬀects
of the drug. Mycophenolate mofetil (MMF) was found to
be safe and eﬀective in controlling cystoid macular oedema
and in reducing the uveitis relapse rate in patients not
responding to traditional immunosuppressants [70]. On the
other hand, an open study reported no beneﬁt in mucocu-
taneous disease [71]. MMF is generally well tolerated; the
most common side eﬀects involve gastrointestinal and gen-
itourinary symptoms. Other reported less frequent adverse
events include neurologic, cutaneous, cardiorespiratory, and
metabolic reactions. Rarely, severe leukopenia has also been
reported. Autologous hematopoietic stem cell transplantation
has recently been reported as a successful treatment option
forsevere/refractorypatientswithintestinal[72],pulmonary
[73], and neurologic [74] involvements. Open studies with
Pentoxifylline reported good results on mucocutaneous
symptoms. However, recurrences occurred in all patients
after discontinuation of treatment. Pentoxifylline has also
been described as alternative treatments for ocular lesions
in few patients with BD [75, 76]. Sulfasalazine (2–4gr/day)
was reported to be an eﬀective choice for the treatment of
gastrointestinal involvement [77].
2.3. Surgical Treatment. Although various treatment modal-
ities appear, surgical intervention often is indicated for
arterial aneurysms. In patients with recurrent or mas-
sive hemoptysis, surgery may be necessary. Endovascular
treatment for pseudoaneurysms due to BD seems to be
an eﬀective choice when the disease activity is strictly
controlled with immunosuppressive therapy [78, 79]. In
other serious consequences, such as gastrointestinal bowel
perforation, enterocutaneous ﬁstula formation, thrombotic
obstruction in large-caliber vessels, cardiac involvement, and
complications of eye involvement such as glaucoma, vitreous
opacities, surgery may also be the only possible remedy
[19, 80].
3. Evidenced-BasedAlgorithmic Treatment
ApproachinBehc ¸et’sDisease
Activity spectrum of systemic therapeutic agents on BD in
randomized, controlled studies is summarized in Table 1.
A stepwise, symptom-based, algorithmic approach, mainly
basedoncontrolledstudiesandourclinicalexperienceinthis
ﬁeld, is summarized below and in Tables 2–6.
3.1. Mucocutaneous Disease. Colchicine should be the ﬁrst
choice in the treatment of GUs and/or EN, especially in
female patients [38]. If it is not eﬀective or patient is
male, colchicine can be combined with benzathine penicillin
[40, 41]. In the presence of OUs with or without other
mucocutaneous lesions, this combination should also be the
starting point.
Short-term corticosteroids in combination with other
drugs such as colchicine can be used as alternatives in
the treatment of acute attacks of mucocutaneous lesions
[18]. Dapsone can also be used at this stage as an eﬀective
compound [44]. Patients with severe mucocutaneous disease
or those who are unresponsive to the respected treatments
can be treated with azathioprine [46]. Thalidomide [45]i s
aneﬀectivechoice.However,becauseofpotentialsideeﬀects,
it should be used cautiously in selected patients. It is wise to
keepinmindthatENworsensduringthalidomidetreatment.
Rebamipide [42], zinc sulfate [43], and Pentoxifylline
[75] can be used as 3rd-line treatment choices. However,
there is still a need for well-organised newer studies for
these agents. In severe cases and/or unresponsive cases to the
other treatments, methotrexate [66], cyclosporin [52], and
b i o l o g i c a l ss u c ha sI F N[ 54] and anti-TNF-α agents [62, 64]
can be used to control the disease.
Antimicrobial agents [20–26], sucralfate [27]a n dc o r -
ticosteroids [19] especially in OUs, and pimecrolimus [28,
29] in GUs can be selected as 1st-line topical treatment
choices. Anti-inﬂammatory agents, amlexanox, anaesthetics,Pathology Research International 7
Table 1: Activity spectrum of systemic therapeutic agents on Behc ¸et’s disease in randomized, controlled studies.
Treatment Dose Indication and reference
Corticosteroids versus placebo 40mg/every 3w Decrease the frequency of EN in women [36]
Colchicine versus placebo
1–2mg/d
Decreases the frequency of EN and eﬀective on arthralgia [37]
Reduces the occurrence of GUs, EN, and arthritis in women and
the occurrence of arthritis in men [38]
1mg/d Decrease in overall disease activity index and signiﬁcant
improvement in OUs, GUs, PPLs, and EN [39]
Colchicine versus Colchicine +
Benzathine penicillin 1–2mg/d; 1.2MU/3w
Combined treatment more eﬀective in reducing frequency of
arthritic episodes, duration and frequency of OUs and EN, and
the frequency of GUs [40]
Colchicine versus Benzathine penicillin
versus Colchicine + Benzathine penicillin 1mg/d;1.2MU/mo Combined use of colchicine and benzathine penicillin
treatment more eﬀective than colchicine or penicillin alone [41]
Rebamipide versus placebo 300mg/d Reduces the number of OUs and pain [42]
Zinc sulfate versus placebo 300mg/d Signiﬁcant improvement in the clinical manifestations index of
mucocutaneous lesions [43]
Dapsone versus placebo 100mg/d
Eﬀective on the number, healing time and frequency of OUs,
number of GUs, and frequency of EN and PPLs. Suppresses
arthritis and epididymitis [44]
Thalidomide versus placebo 100–300mg/d Sustained remission of OUs, GUs, and PPLs [45]
Azathioprine versus placebo 2,5mg/kg/d Reduces the occurrence of OUs, GUs, arthritis, and ocular
symptoms. Prevents the development of new eye disease [46]
Cyclophosphamide + Corticosteroids
versus Corticosteroids 1g/m 2/mo Combined treatment of CCP and corticosteroids more eﬀective
in eye disease than corticosteroids alone [47]
Cyclosporin A versus Colchicine 10mg/kg/d
CyA more eﬀective on the severity and frequency of OUs, GUs,
and PPLs. Superior to colchicine in decreasing the frequency
and severity of ocular attacks [48]
Cyclosporin A versus conventional
treatments (prednisolon, chlorambucil) 10mg/kg/d
CsA more eﬀective than conventional therapy in ocular disease,
however, conventional therapy superior to CyA in controlling
OUs, GUs, and arthritis [49]
Cyclosporin A versus conventional
treatments (prednisolon, chlorambucil) 10mg/kg/d Improvement of hearing loss in 25% of patients receiving CyA
treatment [50]
Cyclosporin A versus Cyclophosphamide 5mg/kg/d A signiﬁcant improvement in VA during the ﬁrst 6 months in
CyA group compared with CCP [51]
Cyclosporin A versus conventional
treatments (prednisolon, Azathioprine) 5mg/kg/d
CyA more eﬀective than conventional therapy in OUs, GUs,
cutaneous lesions, thrombophlebitis as well as articular and
neurologic symptoms [52]
Interferon-α versus placebo 6MU/d-3x/w
Eﬀective on pain and healing time of OUs and frequency of GUs
and PPLs. Also helpful in decreasing frequency and duration of
EN, TFB, and articular symptoms [54]
Etanercept versus placebo 25mg/d-2x/w Reduces the occurrence of OUs, nodular skin lesions, and PPLs
[64]
Rituximab versus cytotoxic combination
therapy
2 1000-mg courses
(15-day interval)
A signiﬁcant improvement in total adjusted disease activity
index in rituximab group [65]
d: day; EN: erythema nodosum; GUs: genital ulcers; Mo: month; OUs: oral ulcers; PPLs: papulopustular lesions; TFB: thrombophlebitis; VA: visual acuity; w:
week.
Table 2: Summary of evidence-based algorithmic treatment for mucocutaneous Behc ¸et’s disease.
1st line
∗Topical: Antimicrobial agents, Sucralfate, Corticosteroids, Pimecrolimus
Systemic: Colchicine, Colchicine + Benzathine penicillin
2nd line
∗Topical: Anti-inﬂammatory agents, Amlexanox
Systemic: Corticosteroids, Dapsone, Azathioprine, Thalidomide
3rd line
∗Topical: Anaesthetics, Silver nitrate
Systemic: Zinc sulfate, Rebamipide, Pentoxifylline, Methotrexate, Cyclosporine-A, IFN-α, Anti-TNF-α
∗Since the eﬀectiveness of topical treatment is generally limited to the application area, it should almost always be associated with systemic therapy.8 Pathology Research International
Table 3: Summary of evidence-based algorithmic treatment for ar-
ticular Behc ¸et’s disease.
1st line Colchicine, Colchicine + Benzathine penicillin, or
anti-inﬂammatory analgesics
2nd line Azathioprine, Corticosteroids
3rd line Methotrexate, Salazopyrine, IFN-α, Anti-TNF-α
Table 4: Summary of evidence-based algorithmic treatment for
ocular Behc ¸et’s disease.
1st line
∗Topical: corticosteroids + mydriatics ± cycloplegic
agents
Systemic: Corticosteroids, Cyclosporine-A,
Azathioprine
2nd line IFN-α, Anti-TNF-α
3rd line Methotrexate, Mycophenolate mofetil,
Cyclophosphamide, Rituximab
∗Topicaltreatmentasasoleagentshouldberestrictedtothosewhohasmild
uveitis (anterior uveitis).
Table 5: Summary of evidence-based algorithmic treatment for
Vasculo-Behc ¸et disease.
1st line Corticosteroids, Azathioprine, Cyclophosphamide,
2nd line Anti-TNF-α
3rd line Anticoagulation, Antiplatelets
and silver nitrate [30–33] are other alternatives for topical
treatment of mucocutaneous lesions. However, it is very
important to ensure for clinician that topical treatment, with
a great possibility, has only local eﬀects and should almost
always be associated with systemic therapy.
Evidenced based algorithmic treatment approach for
mucocutaneous Behc ¸et’s disease is summariezed in Table 2.
3.2. Articular Disease. Evidenced-based algorithmic treat-
ment approach for articular Behc ¸et’s disease is summariezed
in Table 3.
Colchicine should be the ﬁrst choice [37, 38]. Additional
use of benzathine penicillin or anti-inﬂammatory analgesics
can be the next step [40, 41].
In unresponsive cases, azathioprine [46] can be an alter-
native. Low dose corticosteroids, and even intraarticular
corticosteroid injections in monoarticular involvement, can
also be used as 2nd-line treatment [77, 81].
Although controlled studies are still lacking, methotrex-
ate and salazopyrine are used successfully in the clinical
practice [77]. IFN-α [55] and anti-TNF-α agents [62] are the
other alternatives.
3.3. Ocular Disease. Evidenced-based algorithmic treatment
approach for ocular Behc ¸et’s disease is summarized in
Table 4.
Ocular involvement requires special attention and usu-
ally aggressive treatment since it has the highest mor-
bidity. In mild uveitis such as anterior uveitis, topically
applied corticosteroid eye drops together with mydriatics
Table 6: Summary of evidence-based algorithmic therapy for
Neuro-Behc ¸et’s disease.
1st line Corticosteroids
2nd line Azathioprine, cyclophosphamide, Anti-TNF-α,I F N - α
3rd line Methotrexate, Anticoagulation
Table 7: Summary of evidence-based algorithmic therapy for gas-
trointestinal Behc ¸et’s disease.
1st line Sulfasalazine, corticosteroids
2nd line Azathioprine
3rd line Anti-TNF-α
or cycloplegic agents can often control the disease [19].
Systemic corticosteroids should be the next step. It is wise to
rememberthatsystemiccorticosteroidsarealsousedinacute
inﬂammatory ocular attacks of posterior uveitis, panuveitis,
and retinal vasculitis [18]. Systemic corticosteroids should
be used in brief courses for long term because of well-
known side eﬀect proﬁle. Unresponsive cases, those with
posterior uveitis, or those who develop chronic, steroid-
dependent intraocular inﬂammation (given the deleterious
eﬀects of chronic steroid administration to the eye) require
more aggressive treatment. Immunosuppressives such as
azathioprine [46] and cyclosporine [48, 49, 51] are the main
choices. Cyclosporine together with corticosteroids can be
used eﬀectively. Azathioprine and cyclosporine can also be
combined in those patients whose eye disease is refractory to
treatment [18].
As we mentioned before, IFN-α or anti-TNF-α treat-
ments can be used in case when the immunosuppressives do
not control the disease [82].
Methotrexate, MMF, cyclophosphamide, and rituximab
can be used in selected patients as a 3rd-line therapy [47, 65,
69, 70].
In the most severe cases with retinal vasculitis or
macular involvement, CyA or anti-TNF-α treatments can be
combined with azathioprine and corticosteroids. Cyclophos-
phamideandIFN-αwithorwithoutcorticosteroidsareother
alternatives for the treatment of severe eye disease [18].
3.4. Severe Disease. Although several promising therapies
are evolving, the treatment of severe disease is not entirely
satisfactory and treatment of those remains predominantly
empirical. Severe disease has relatively lower incidence.
Because of the limited number of patients enrolled in
studies in this area statistical comparisons were usually not
made. These factors make recommendation of individual
treatments diﬃcult for these involvements.
Evidenced-based algorithmic treatment approach of
Behc ¸et’s disease with large vessel, neurologic, and gastroin-
testinal involvement is summarized in Tables 5–7.
3.4.1. Large Vessel Involvements. In the presence of deep
vein thromboses, azathioprine can be used. In severer cases
with inferior vena cava or superior vena cava syndrome
and Budd-Chiairi syndrome cyclophosphamide as monthlyPathology Research International 9
pulse treatment should be added to the treatment. It is
unclear the eﬀectiveness of additional use of antiplatelets or
anticoagulation [18, 77, 81, 82].
In arterial involvement, corticosteroids together with
cyclophosphamide are generally preferred to control the
disease. Anticoagulation should not be given in the presence
of pulmonary arterial aneurysm because of the danger of
bleeding [77, 81, 82]. Anti-TNF-α agents, especially inﬂix-
imab, can be alternative [18].
Surgery may be necessary in life-threatening conditions
such as growing aneurysm, acute rupture [81].
3.4.2.NeurologicInvolvements. Inparenchymalinvolvement,
corticosteroids (100mg/d or 1gx 5 days as pulse treatment)
should be the ﬁrst choice. Azathioprine is usually com-
bined with corticosteroids. In severe or unresponsive cases,
cyclophosphamidecanbegivenadditionally[83].Anti-TNF-
α agents and IFN-α are other new eﬀective alternative agents
[19]. Methotrexate is another treatment alternative [67, 68].
In venous sinus thrombosis corticosteroids with or with-
outimmunosuppressivesarethemaintreatmentapproaches.
In this situation additional use of anticoagulation is also
suggested [81, 83].
3.4.3. Gastrointestinal Disease. Sulfasalazine and corticos-
teroids seem to be the 1st-line treatment options [77].
Azathioprine can be used eﬀectively in unresposive cases.
Anti-TNF-α treatments, especially inﬂiximab, seem to be
new and eﬀective alternative. Surgery should be selected
in those patients with perforation and intractable bleeding
[18, 81].
In conclusion, treatment of BD has become much
more eﬀective in recent years. Due to recent advances in
understanding the pathogenesis of the underlying disease
and availability of a wide spectrum of therapeutic agents,
alleviation of most symptoms, control of the disease, and,
even, modiﬁcation of the course of the disease are now
possible.
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